
## Masami Watanabe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1226810/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Down-regulation of Inhibition of Differentiation-1 via Activation of Activating Transcription Factor 3 and Smad Regulates REIC/Dickkopf-3–Induced Apoptosis. Cancer Research, 2008, 68, 8333-8341.	0.9	85
2	MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-I®B and ROS formation upon ligand binding. Clinical and Experimental Metastasis, 2016, 33, 609-627.	3.3	58
3	Immunological aspects of REIC/Dkk-3 in monocyte differentiation and tumor regression. International Journal of Oncology, 2009, 34, 657-63.	3.3	45
4	Adenovirus-mediated REIC/Dkk-3 gene therapy: Development of an autologous cancer vaccination therapy (Review). Oncology Letters, 2014, 7, 595-601.	1.8	32
5	Ad-REIC Gene Therapy: Promising Results in a Patient with Metastatic CRPC following Chemotherapy. Clinical Medicine Insights: Oncology, 2015, 9, CMO.S23252.	1.3	27
6	Potential of adenovirusâ€mediated <scp>REIC</scp> / <scp>Dkk</scp> â€3 gene therapy for use in the treatment of pancreatic cancer. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 973-983.	2.8	26
7	Significant association between the Axin2 rs2240308 single nucleotide polymorphism and the incidence of prostate cancer. Oncology Letters, 2014, 8, 789-794.	1.8	24
8	A novel gene expression system strongly enhances the anticancer effects of a REIC/Dkk-3-encoding adenoviral vector. Oncology Reports, 2014, 31, 1089-1095.	2.6	24
9	Pelvic magnetic resonance imaging parameters predict urinary incontinence after robotâ€assisted radical prostatectomy. LUTS: Lower Urinary Tract Symptoms, 2019, 11, 122-126.	1.3	24
10	Anti-Cancer Effects of REIC/Dkk-3-encoding Adenoviral Vector for the Treatment of Non-small Cell Lung Cancer. PLoS ONE, 2014, 9, e87900.	2.5	23
11	N′-[4-(dipropylamino)benzylidene]-2-hydroxybenzohydrazide is a dynamin GTPase inhibitor that suppresses cancer cell migration and invasion by inhibiting actin polymerization. Biochemical and Biophysical Research Communications, 2014, 443, 511-517.	2.1	19
12	The cysteine-rich core domain of REIC/Dkk-3 is critical for its effect on monocyte differentiation and tumor regression. Oncology Reports, 2015, 33, 2908-2914.	2.6	18
13	A super gene expression system enhances the anti-glioma effects of adenovirus-mediated REIC/Dkk-3 gene therapy. Scientific Reports, 2016, 6, 33319.	3.3	16
14	Advanced two-step transcriptional amplification as a novel method for cancer-specific gene expression and imaging. Oncology Reports, 2011, 26, 769-75.	2.6	15
15	Dynamin 1 is important for microtubule organization and stabilization in glomerular podocytes. FASEB Journal, 2020, 34, 16449-16463.	0.5	14
16	A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment. Oncology Reports, 2015, 33, 1585-1592.	2.6	12
17	Promising therapeutic efficacy of a novel reduced expression in immortalized cells/dickkopfâ€3 expressing adenoviral vector for hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 1769-1777.	2.8	11
18	Promising Gene Therapy Using an Adenovirus Vector Carrying REIC/Dkk-3 Gene for the Treatment of Biliary Cancer. Current Gene Therapy, 2020, 20, 64-70.	2.0	11

MASAMI WATANABE

#	Article	IF	CITATIONS
19	Tumor suppressor REIC/DKK-3 and co-chaperone SGTA: Their interaction and roles in the androgen sensitivity. Oncotarget, 2016, 7, 3283-3296.	1.8	10
20	<i>In vitro</i> anticancer effects of alpelisib against PIK3CA‑mutated canine hemangiosarcoma cell lines. Oncology Reports, 2022, 47, .	2.6	9
21	Exogenous DKK‑3/REIC inhibits Wnt/β‑catenin signaling and cell proliferation in human kidney cancer KPK1. Oncology Letters, 2017, 14, 5638-5642.	1.8	8
22	Loss of psoas major muscle volume during systemic chemotherapy is related to worse prognosis in testicular cancer. Japanese Journal of Clinical Oncology, 2019, 49, 183-189.	1.3	7
23	Correlation between lumbar skeletal muscle size and urinary incontinence after radical prostatectomy. LUTS: Lower Urinary Tract Symptoms, 2020, 12, 245-252.	1.3	7
24	Synergistic antiâ€pancreatic cancer immunological effects by treatment with reduced expression in immortalized cells/dickkopfâ€3 protein and peripheral blood mononuclear cells. Journal of Gastroenterology and Hepatology (Australia), 2016, 31, 1154-1159.	2.8	6
25	R132 mutations in canine isocitrate dehydrogenase 1 (IDH1) lead to functional changes. Veterinary Research Communications, 2018, 42, 49-56.	1.6	6
26	Molecular cloning of canine co-chaperone small glutamine-rich tetratricopeptide repeat-containing protein α (SGTA) and investigation of its ability to suppress androgen receptor signalling in androgen-independent prostate cancer. Veterinary Journal, 2015, 206, 143-148.	1.7	5
27	Overexpression of REIC/Dkk-3 suppresses the expression of CD147 and inhibits the proliferation of human bladder cancer cells. Oncology Letters, 2017, 14, 3223-3228.	1.8	5
28	Canine REIC/Dkk-3 interacts with SGTA and restores androgen receptor signalling in androgen-independent prostate cancer cell lines. BMC Veterinary Research, 2017, 13, 170.	1.9	5
29	Robust cancer-specific gene expression by a novel cassette with hTERT and CMV promoter elements. Oncology Reports, 2017, 38, 1108-1114.	2.6	5
30	The canine RAD51 mutation leads to the attenuation of interaction with PALB2. Veterinary and Comparative Oncology, 2020, 18, 247-255.	1.8	4
31	Internalization of AMPA-type Glutamate Receptor in the MIN6 Pancreatic β-cell Line. Cell Structure and Function, 2020, 45, 121-130.	1.1	4
32	Feasible kidney donation with living marginal donors, including diabetes mellitus. Immunity, Inflammation and Disease, 2021, 9, 1061-1068.	2.7	4
33	A novel in situ permeation system and its utility in cancer tissue ablation. International Journal of Oncology, 2015, 47, 875-883.	3.3	3
34	Endogenous Leu332Gln mutation in p53 disrupts the tetramerization ability in a canine mammary gland tumor cell line. Oncology Reports, 2018, 40, 488-494.	2.6	3
35	Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer. Asian Journal of Urology, 2021, 8, 280-288.	1.2	3
36	The number of glutamines in the Nâ€ŧerminal of the canine androgen receptor affects signalling intensities. Veterinary and Comparative Oncology, 2021, 19, 399-403.	1.8	3

MASAMI WATANABE

#	Article	IF	CITATIONS
37	Impact of Sarcopenia on Erectile Function after Nerve-Sparing Robot-Assisted Radical Prostatectomy. World Journal of Men?s Health, 2021, 39, 673.	3.3	3
38	Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability. Oncology Letters, 2020, 20, 1-1.	1.8	2
39	Medical uses for silver nitrate in the urinary tract (Review). World Academy of Sciences Journal, 2022, 4, .	0.6	1
40	Functional alteration of canine isocitrate dehydrogenase 2 (IDH2) via an R174K mutation. Journal of Veterinary Medical Science, 2018, 80, 85-91.	0.9	0
41	A second opinion pathology review improves the diagnostic concordance between prostate cancer biopsy and radical prostatectomy specimens. Urology Annals, 2021, 13, 119.	0.6	0
42	Medical uses for phenol in the urinary tract: A possible forgotten treatment (Review). Medicine International, 2021, 1, .	0.6	0
43	Novel canine isocitrate dehydrogenase 1 mutation Y208C attenuates dimerization ability. Oncology Letters, 2020, 20, 351.	1.8	0
44	A Clinical Trial Evaluating the Usefulness of Tailored Antimicrobial Prophylaxis Using Rectal-culture Screening Media Prior to Transrectal Prostate Biopsy: A Multicenter, Randomized Controlled Trial. Acta Medica Okayama, 2021, 75, 663-667.	0.2	0
45	Clinical Efficacy and Safety of Sitafloxacin 200 mg Once Daily for Refractory Genitourinary Tract Infections Acta Medica Okayama, 2021, 75, 763-766.	0.2	0
46	Intravesical indwelling lidocaine‑releasing devices for IC/BPS (Review). World Academy of Sciences Journal, 2022, 4, .	0.6	0